Xtl生物制药 XTLB 深 沪
等待开盘 04-01 09:30:00 美东时间
2.41
-0.200
-7.66%
华盛通- 最 高2.51
- 今 开2.51
- 成交量 8687股
- 最 低 2.41
- 昨 收 2.61
- 总市值 2280.45万
- 52周最高 10.2796
- 市盈率 静 --
- 换手率 0.09%
- 52周最低 2.1204
- 委 比 14.11%
- 总股本 946.24万
- 历史最高 151.00
- 量 比 0.34
- 振 幅 3.83%
- 历史最低 2.1204
- 每 手 1
- 风险率 1.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多XTL Biopharmaceuticals announces 1-for-4 ADS ratio change
XTL Biopharmaceuticals (XTLB) will change its ADS ratio from 1:100 to 1:400 effective March 25, 2026. The move is equivalent to a 1-for-4 reverse ADS split for shareholders. No fractional ADSs will be...
03-21 04:19
XTL Biopharma To Implement 1-For-4 Reverse ADS Split, Effective March 25, 2026
XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it plans to change the ratio of its American Depositary Shares ("ADSs") to its ordinary shares, par
03-21 04:10
XTL Biopharmaceuticals Announces ADS Ratio Change
XTL Biopharmaceuticals Ltd. announced plans to change its American Depositary Shares (ADS) ratio from 1 ADS to 100 ordinary shares to 1 ADS to 400 ordinary shares, effective March 25, 2026. This change is equivalent to a 1-for-4 reverse ADS split. ADS holders will receive 1 new ADS for every 4 existing ADSs, with no fees charged. Fractional ADSs will be sold and proceeds distributed to holders. The company expects its ADS trading price to increas...
03-20 20:10
Beyond Air halts sale of NeuroNOS subsidiary to XTL Biopharmaceuticals
Beyond Air (XAIR) has terminated an agreement with XTL Biopharmaceuticals to sell its majority ownership interest in NeuroNOS subsidiary The companies had entered into a letter of intent in January ...
03-10 19:59
Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.
Beyond Air, Inc. has terminated its proposed transaction with XTL Biopharmaceuticals Ltd. regarding its NeuroNOS subsidiary. The letter of intent expired on March 9, 2026, and no definitive agreement was reached. Beyond Air remains committed to maximizing the value of NeuroNOS and advancing its core nitric oxide platform and LungFit programs.
03-10 11:30
XTL Biopharmaceuticals Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing
According to Nasdaq staff, XTLB qualifies as a "public shell" and does not warrant continued listing of its ADS.
02-28 05:34
XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing
XTL Biopharmaceuticals Ltd. has received a delisting notice from Nasdaq, citing the company as a "public shell" due to its wholly owned subsidiary, The Social Proxy, being liquidated. The company plans to request a hearing to appeal the delisting decision, which would temporarily prevent the suspension of its ADSs. Additionally, the company failed to meet shareholder equity and bid price requirements, further supporting Nasdaq's delisting decisio...
02-27 21:30
Beyond Air Inc. Q3 revenue doubles to USD 2.2 million
Beyond Air Inc. Q3 revenue doubles to USD 2.2 million Beyond Air Inc. reported fiscal third quarter (Q3) revenue of USD 2.2 million, representing a more than twofold increase year-over-year. The company maintained its fiscal year (FY) 2026 revenue guidance at USD 8 million to USD 10 million. Net los
02-13 20:30
XTL Update on Recent Developments
XTL Biopharmaceuticals Ltd. is working to finalize the acquisition of 85% of NeuroNOS Ltd. from Beyond Air Inc., following a binding letter of intent signed on January 13, 2026. The company plans to hold a shareholders' meeting on February 17, 2026, to approve a private placement of up to $2 million. The transaction and private placement aim to address the company's deficiency under Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2.5...
01-29 21:05
XTL announces receipt of Nasdaq notification
XTL Biopharmaceuticals (NASDAQ:XTLB) said on Friday it received a notice from Nasdaq on January 20, 2026, that the company is not in compliance with the continued listing requirements to maintain the ...
01-24 05:25
